The Nanoparticle That Skips the Liver

Penn engineers redesign nanoparticles to target lymph nodes, cutting liver delivery tenfold with no loss of immune potency

15 May 2026

mRNA delivery has always had a navigation problem. Left to current formulations, nanoparticles tend to pile up in the liver, useful for some applications, but a persistent obstacle for vaccines and immunotherapies that need to reach lymph nodes. A team at the University of Pennsylvania may have found a way around it.

Published in March 2026 in the Journal of the American Chemical Society, their research introduces aroLNPs: lipid nanoparticles redesigned from the inside out to redirect mRNA traffic. At the center of the advance is the ionizable lipid, the component responsible for helping mRNA cross cell membranes. Grafting aromatic ring structures onto this lipid and adding bioreducible disulfide bonds that break apart once inside a cell produced particles that behave differently from anything in clinical use today.

Animal model results were striking. Compared to the formulation behind Moderna's COVID-19 vaccine, the best-performing aroLNPs delivered tenfold less mRNA to the liver, while lymph node accumulation stayed equally strong. Antibody responses matched those of approved formulations, and systemic inflammatory markers linked to side effects like fever and fatigue dropped significantly.

"The more particles that reach the lymph nodes, the fewer particles each dose needs," said Michael J. Mitchell, Associate Professor in Bioengineering at Penn and the study's senior author. That logic carries real clinical weight. Lower doses mean fewer adverse effects, a meaningful advantage for cancer vaccines and autoimmune therapies, where precision delivery has long been a prerequisite for progress rather than a bonus.

Timing matters, too. Across Europe, mRNA pipelines are moving fast into oncology and rare diseases, and delivery precision has become the critical gap between promising science and regulatory approval. AroLNPs offer a chemically grounded, scalable pathway to close it.

Still, all findings remain in animal models. Translating results to human trials and manufacturing aroLNPs at GMP standards represent real technical work ahead, but the engineering logic is sound, and the direction is clear.